Slide 1: Stock exchange filing cover letter
April 27, 2023 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Re
Slide 2: Investor Presentation Q4 & FY23
Investor Presentation Q4 & FY23
Slide 3: Financial Performance Review
Financial Performance Review
Slide 4: Q4 FY23 – Highlights
Q4 FY23 – Highlights “At Glenmark Life Sciences we have concluded the financial year 2023 on a high note delivering revenue from operations of Rs. 621 Cr which grew by 15% on Dr. Yasir Rawjee sequential basis and 21% YoY. The growth was driven by strong momentum in the Managing Director & Generic AP
Slide 5: Q4 & FY23 Performance
Q4 & FY23 Performance Steady growth with stable margins PAT Revenue EBITDA EBITDA PAT EPS (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹ Milli o n s) PAT Margin (In ₹) EBITDA Margin 33.7% 22.2% 21.0% 23.6% 28.7% 31.9% 30.2% 28.1% 19.4% 5,407 19.2% 5,141 5,093 4,899 8.87 8.72 8.57 1,087 1,069 8.07 1,050
Slide 6: P&L Highlights – Q4 & FY23
P&L Highlights – Q4 & FY23 Particulars (In ₹ Millions) Q4 FY23 Q3 FY23 QoQ Q4 FY22 YoY FY23 FY22 YoY Revenue from Operations 6,213 5,407 14.9% 5,141 20.9% 21,612 21,232 1.8% Gross Profit 3,409 2,759 23.6% 2,589 31.7% 11,471 10,803 6.2% Gross Profit (%) 54.9% 51.0% 50.4% 53.1% 50.9% Other Income 28 6
Slide 7: Strong Returns Indicators
Strong Returns Indicators ROICE Fixed Assets Turnover Working Capital Days 202 40% 173 176 171 35% 36% 152 3.3 3.4 31% 34% 2.9 2.9 2.7 98 102 104 99 89 116 152 120 116 136 -47 -48 -43 -53 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 -67 • ROICE is tracking at 33.5% – Higher capital employed dri
Slide 8: Financial Performance Track Record
Financial Performance Track Record Robust growth and profitability indicators over the years Revenue EBITDA PAT EPS (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹) EBITDA PAT EBITDA Margin PAT Margin 21.6% 31.0% 20.4% 19.7% 31.4% CAGR 11.4% 31.5% 29.7% 20.8% 18.6% 21,612 21,232 38.1
Slide 9: Business Performance Review
Business Performance Review
Slide 10: Segment Performance – Generic & CDMO business
Segment Performance – Generic & CDMO business Generic API CDMO (Rev enu e In ₹ Milli o n s) (Rev enu e In ₹ Milli o n s ) 5,299 435 4,799 309 279 4,590 243 4,533 4,448 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 • Generic API revenues in Q4FY23 increased 10.4% • C
Slide 11: Segment Performance – GPL vs. External
Segment Performance – GPL vs. External External GPL GPL External (In ₹ Milli o n s) (In ₹ Milli o n s) % of Total Revenue % of Total Revenue 36.0% 37.2% 34.0% 3,755 3,814 29.0% 3,286 3,242 26.0% 74.0% 71.0% 1,855 1,657 64.0% 66.0% 62.8% 1,594 1,338 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q4 FY22 Q1
Slide 12: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix Market Mix Therapeutic Area Mix 18% 19% 27% 28% 25% 28% 29% 35% 39% 39% 6% 8% 4% Others 8% 7% 5% 6% Emerging 10% 3% Pain Management 4% Markets 15% 14% 14% 12% Diabetes 15% 82% 81% 73% 72% 75% CNS Regulated Markets CVS 43% 42% 40% 37% 36% Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY2
Slide 13: Company Overview
Company Overview LIFE SCIENCES
Slide 14: Global Footprint
Global Footprint • Filed 468 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 60+ 350+ 30+ 93 112 155 10+ 18 120+ 10+ 50+ 19 71 (Brazil) India – Mix of Regulated Number of Number of customers As of March 31, 2023 R
Slide 15: Quality-focused, compliant manufacturing & R&D infrastructure
Quality-focused, compliant manufacturing & R&D infrastructure Manufacturing Infrastructure R&D Infrastructure Annual Installed Capacity Last USFDA Mahape, Navi Mumbai Location Approvals (Mar-23) Inspection Date R&D for new product development and complex USFDA, MHRA (UK), FIMEA (Finland), molecule
Slide 16: R&D Capabilities
R&D Capabilities Cumulative Filing Status R&D Spend (In ₹ Milli o n s) North Therapy Europe Japan Brazil Australia ROW Total America R&D Spend CVS 37 31 4 18 10 28 128 As % to Sales CNS 35 21 8 13 1 13 91 3.0% Diabetes 9 4 8 12 33 652 2.7% 2.7% Pain Management 1 2 4 1 8 16 2.6% 2.1% Others 73 35 6 2
Slide 17: Strategy Going Forward
Strategy Going Forward / LIFE SCIENCES
Slide 18: Strategic Growth Levers
Strategic Growth Levers 1 Gx API Business New product launches Geographical expansion Focus on new markets becoming more regulated New Growth levers 2 Pursue 2nd source opportunities with top generic players Ramp up CDMO portfolio Expand into complex API platforms Iron compounds Onco
Slide 19: Future Capacity Expansion Plan
Future Capacity Expansion Plan Operational Expansion Type Division Location Current Capacity Status & Planned Capacity Timelines 192 KL capacity added in Brownfield Intermediate Ankleshwar 742.2 KL Mar 23.Under Construction Q3 FY24 208 KL CTE Received for Greenfield API Solapur - FY24 - FY26 1,000 K
Slide 20: Thank You
Thank You FOR FURTHER INFORMATION CONTACT Email: complianceofficer@glenmarklifesciences.com ERNST & YOUNG LLP – INVESTOR RELATIONS DIWAKAR PINGLE RAHUL THAKUR Email: Diwakar.Pingle@in.ey.com Email: rahul.thakur@in.ey.com Mobile: +91 98333 19957 CORPORATE OFFICE: REGISTERED OFFICE: T: 91 22 68297979